Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Animus Cure
Cranbury, NJ, United States
- Ownership
- Private
- Employees
- ~600
- Development stage
- Other
01
Overview
Amicus commercializes Galafold (migalastat) for Fabry disease, and Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for late-onset Pompe disease; positive long-term Phase 1/2 and pivotal Phase 3 data for AT-GAA program in Pompe disease[3]. Strong pipeline in gene therapies for rare diseases[2].
- Therapeutic areas
- NeurologyRare Diseases
- Modalities
- Small moleculeEnzyme replacement therapyGene therapyBiologic
- Industry
- Biotech
02
Partnerships
University of Pennsylvania (expanded gene therapy collaboration for 12 additional rare diseases)[2]Ultragenyx (Mepsevii licensing in Japan)[2]
Beyond the preview
Go deeper on Animus Cure.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Animus Cure.